Creating DNAm Algorithms Using the Illumina Methylation Screening Array (MSA)

Most established DNA methylation (DNAm) biomarkers were developed on legacy Illumina EPIC arrays. The Infinium Methylation Screening Array (MSA) offers a lower-cost, higher-throughput alternative with reduced probe content, but EPIC-trained algorithms cannot be assumed to transfer directly. Here we present a reproducibility-based framework for developing and transferring DNAm algorithms on the MSA. Using paired biological replicates profiled on EPICv1 and MSA (1,764 EPICv1-MSA sample pairs, plus within-array MSA replicates on the same and different beadchips), we quantified probe-level agreement using mean absolute error (MAE) and intraclass correlation coefficients (ICC). Of 140,150 CpG sites shared between EPICv1 and MSA, 40,786 (29.1%) met both stability criteria (MAE 0.6). This stable feature space supported two modelling streams. First, we trained 134 epigenetic biomarker proxies (EBPs) natively on MSA, with and without kernel principal component analysis (kPCA) for sample-level harmonisation. All 134 reached same-beadchip ICC(2,1) >= 0.80 (median 0.97) and 96.3% reached different-beadchip ICC(2,1) >= 0.60 (median 0.81), with a median Spearman correlation of 0.48 against observed values. Among the 72 kPCA-selected models with a comparable stable-probe baseline, 70 (97%) showed higher cross-beadchip ICC (median improvement +0.18). Second, we transferred three established clocks using model-specific strategies: OMICmAge and SystemsAge were retrained to estimate their EPICv1-derived values (held-out test-set rho = 0.944 and 0.912-0.949), whereas DunedinPACE required stable-probe normalisation and robust linear calibration, which raised cross-array ICC(2,1) from 0.784-0.810 to 0.891-0.925 and reduced MAE from 0.085-0.089 to 0.041-0.050 across three sample sets. Reduced probe content does not preclude reproducible DNAm biomarker measurement, and transfer strategy must be matched to model architecture.